PharmCAT.NET

Biostatistics, pharmacokinetics and clinical trials.

  • Home page
  • Blog
  • Contacts
  • Agreement & Confidentiality

IBM SPSS Extension: R Project PowerTOST library

Posted on December 31, 2018December 31, 2018 by frozencat

IBM SPSS Extension PowerTOST R Project library. Syntax command: POWERTOST.

Version: 1.0.0

Functions:

  • power.TOST
  • sampleN.TOST
  • CVfromCI

Дизайны:

  • parallel
  • 2×2
  • 2x2x4

Скачать/Download

GitHUB: https://github.com/PharmCat/SPSSPowerTOST

Categories: Blog, SPSS

Post navigation

Next Post:

Recent Posts

  • IBM SPSS + R Project: Confidence intervals for proportions, independent groups
  • IBM SPSS Extension: R Project PowerTOST library

Галерея

20170730 121730
20180202 160131
20180814 153430
IMG-20170806-WA0005
DJI 0006
20180202 162006
  • Human medicines European public assessment report (EPAR): Besremi, ropeginterferon alfa-2b, Date of authorisation: 15/02/2019, Revision: 8, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-21
  • Human medicines European public assessment report (EPAR): Voriconazole Accord, voriconazole, Date of authorisation: 16/05/2013, Revision: 22, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-21
  • Foshan Yiying Hygiene Products Co., Ltd. - 715548 - 10/10/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-21 By FDA
  • All American Wellness - 715991 - 09/09/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-21 By FDA
  • www.usmedschoice.com - 716055 - 10/06/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-21 By FDA
  • Acme United Corporation - 712324 - 10/10/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-21 By FDA
  • Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 12, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-21
  • BRS Analytical Services, LLC - 711133 - 09/17/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-21 By FDA
  • Timeline of Selected FDA Activities and Significant Events Addressing Substance Use and Overdose Prevention
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-21 By FDA
  • Melcare Biomedical Pty Ltd - 717968 - 10/09/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-21 By FDA
  • Human medicines European public assessment report (EPAR): Lemtrada, alemtuzumab, Date of authorisation: 12/09/2013, Revision: 26, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-21
  • Spotlight on CDER Science
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-10-21 By FDA
  • Complete List of Donor Screening Assays for Infectious Agents and HIV Diagnostic Assays
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-10-21 By FDA
  • Human medicines European public assessment report (EPAR): Rayvow, lasmiditan, Date of authorisation: 17/08/2022, Revision: 5, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-21
  • Human medicines European public assessment report (EPAR): Datroway, datopotamab deruxtecan, Date of authorisation: 04/04/2025, Revision: 2, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-10-21
Older posts
Theme: Scaffold by Danny Cooper.